{
    "pmcid": "10054972",
    "qa_pairs": {
        "What is one of the potential therapeutic applications of nanobodies as suggested by the study?": [
            "Intranasal treatment to prevent or treat COVID-19 encephalitis",
            "Oral vaccine development for broad immunity",
            "Topical application for skin-related symptoms",
            "Intramuscular injection for rapid systemic response"
        ],
        "What method was used to map the binding sites of the nanobodies on the SARS-CoV-2 S protein?": [
            "Biliverdin competition assays and peptide arrays",
            "X-ray crystallography and NMR spectroscopy",
            "Cryo-electron microscopy and mass spectrometry",
            "Surface plasmon resonance and ELISA"
        ],
        "What was the primary method of administration for nanobodies in the in vivo efficacy study?": [
            "Intranasal administration",
            "Intravenous injection",
            "Oral administration",
            "Subcutaneous injection"
        ],
        "What were the two sources used to construct the VHH libraries for nanobody generation?": [
            "A llama immunized with bovine coronavirus and another with the SARS-CoV-2 S protein and RBD from the Wuhan strain.",
            "A llama immunized with the Delta variant and another with the Omicron variant.",
            "A llama immunized with the Alpha variant and another with the Beta variant.",
            "A llama immunized with the N-terminal domain and another with the S-2P protein."
        ],
        "Which specific nanobody demonstrated high neutralizing activity and provided significant protection against mortality in mice?": [
            "Nb-39",
            "Nb-21",
            "Nb-45",
            "Nb-12"
        ]
    }
}